Literature DB >> 19504174

Akt is a direct target for myricetin to inhibit cell transformation.

Takuma Kumamoto1, Makoto Fujii, De-Xing Hou.   

Abstract

Akt, a serine/threonine kinase, is a critical regulator in many cellular processes including cell growth, proliferation, and apoptosis. In this study, we found that myricetin, a typical flavonol existing in many fruits and vegetables, could directly target Akt to inhibit cell transformation. Binding assay revealed that myricetin bound to Akt directly by competing with ATP. In vitro and ex vivo data confirmed that myricetin inhibited the phosphorylation and kinase activity of Akt. Molecular modeling suggested that myricetin easily docks to the ATP-binding site of Akt with hydrogen bonds. Signaling analysis data further demonstrated that myricetin inhibited Akt-mediated activator protein-1 (AP-1) transactivation, cyclin D1 expression and cell transformation. Overall, our results indicate that Akt is a direct target for myricetin to inhibit cell transformation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19504174     DOI: 10.1007/s11010-009-0171-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  30 in total

1.  Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells.

Authors:  I K Wang; S Y Lin-Shiau; J K Lin
Journal:  Eur J Cancer       Date:  1999-10       Impact factor: 9.162

2.  Flavonoid intake and colorectal cancer risk in men and women.

Authors:  Jennifer Lin; Shumin M Zhang; Kana Wu; Walter C Willett; Charles S Fuchs; Edward Giovannucci
Journal:  Am J Epidemiol       Date:  2006-08-21       Impact factor: 4.897

Review 3.  Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis.

Authors:  T C Hsu; M R Young; J Cmarik; N H Colburn
Journal:  Free Radic Biol Med       Date:  2000-05-01       Impact factor: 7.376

4.  Myricetin inhibits the induction of anti-Fas IgM-, tumor necrosis factor-alpha- and interleukin-1beta-mediated apoptosis by Fas pathway inhibition in human osteoblastic cell line MG-63.

Authors:  Po-Lin Kuo
Journal:  Life Sci       Date:  2005-10-21       Impact factor: 5.037

5.  Anthocyanidins inhibit activator protein 1 activity and cell transformation: structure-activity relationship and molecular mechanisms.

Authors:  De-Xing Hou; Keiko Kai; Jian-Jian Li; Shigang Lin; Norihiko Terahara; Mika Wakamatsu; Makoto Fujii; Mattew R Young; Nancy Colburn
Journal:  Carcinogenesis       Date:  2003-09-26       Impact factor: 4.944

6.  Myricetin directly targets JAK1 to inhibit cell transformation.

Authors:  Takuma Kumamoto; Makoto Fujii; De-Xing Hou
Journal:  Cancer Lett       Date:  2008-11-07       Impact factor: 8.679

7.  Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin.

Authors:  Shunsuke Tanigawa; Makoto Fujii; De-Xing Hou
Journal:  Free Radic Biol Med       Date:  2007-02-28       Impact factor: 7.376

8.  The role of glycogen synthase kinase 3beta in the transformation of epidermal cells.

Authors:  Cuiling Ma; Jian Wang; Ying Gao; Tian-Wen Gao; Gang Chen; Kimberly A Bower; Mohammed Odetallah; Min Ding; Zunji Ke; Jia Luo
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

9.  Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1.

Authors:  Ki Won Lee; Nam Joo Kang; Evgeny A Rogozin; Hong-Gyum Kim; Yong Yeon Cho; Ann M Bode; Hyong Joo Lee; Young-Joon Surh; G Tim Bowden; Zigang Dong
Journal:  Carcinogenesis       Date:  2007-08-11       Impact factor: 4.944

10.  Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells.

Authors:  Shunsuke Tanigawa; Makoto Fujii; De-Xing Hou
Journal:  Biosci Biotechnol Biochem       Date:  2008-03-07       Impact factor: 2.043

View more
  9 in total

Review 1.  Signal transduction and molecular targets of selected flavonoids.

Authors:  Ann M Bode; Zigang Dong
Journal:  Antioxid Redox Signal       Date:  2013-04-15       Impact factor: 8.401

2.  Development of an HTS-compatible assay for the discovery of ASK1 signalosome inhibitors using alphascreen technology.

Authors:  Emmanuel Sturchler; Weimin Chen; Timothy Spicer; Peter Hodder; Patricia McDonald; Derek Duckett
Journal:  Assay Drug Dev Technol       Date:  2014-05       Impact factor: 1.738

3.  Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells.

Authors:  Julia Wachter; Daniel Neureiter; Beate Alinger; Martin Pichler; Julia Fuereder; Christian Oberdanner; Pietro Di Fazio; Matthias Ocker; Frieder Berr; Tobias Kiesslich
Journal:  Int J Biol Sci       Date:  2011-11-07       Impact factor: 6.580

Review 4.  Molecular Targets Underlying the Anticancer Effects of Quercetin: An Update.

Authors:  Fazlullah Khan; Kamal Niaz; Faheem Maqbool; Fatima Ismail Hassan; Mohammad Abdollahi; Kalyan C Nagulapalli Venkata; Seyed Mohammad Nabavi; Anupam Bishayee
Journal:  Nutrients       Date:  2016-08-29       Impact factor: 5.717

Review 5.  Myricetin: A Dietary Molecule with Diverse Biological Activities.

Authors:  Deepak Kumar Semwal; Ruchi Badoni Semwal; Sandra Combrinck; Alvaro Viljoen
Journal:  Nutrients       Date:  2016-02-16       Impact factor: 5.717

6.  Neurotoxic Effect of Flavonol Myricetin in the Presence of Excess Copper.

Authors:  Anja Sadžak; Ignacija Vlašić; Zoran Kiralj; Marijana Batarelo; Nada Oršolić; Maja Jazvinšćak Jembrek; Ines Kušen; Suzana Šegota
Journal:  Molecules       Date:  2021-02-05       Impact factor: 4.411

7.  Crocetin Exerts Its Anti-inflammatory Property in LPS-Induced RAW264.7 Cells Potentially via Modulation on the Crosstalk between MEK1/JNK/NF-κB/iNOS Pathway and Nrf2/HO-1 Pathway.

Authors:  Yi-Ling Wen; Ziyu He; De-Xing Hou; Si Qin
Journal:  Oxid Med Cell Longev       Date:  2021-09-10       Impact factor: 6.543

Review 8.  Myricetin: targeting signaling networks in cancer and its implication in chemotherapy.

Authors:  Zeeshan Javed; Khushbukhat Khan; Jesús Herrera-Bravo; Sajid Naeem; Muhammad Javed Iqbal; Qamar Raza; Haleema Sadia; Shahid Raza; Munir Bhinder; Daniela Calina; Javad Sharifi-Rad; William C Cho
Journal:  Cancer Cell Int       Date:  2022-07-28       Impact factor: 6.429

Review 9.  Kinase-targeted cancer therapies: progress, challenges and future directions.

Authors:  Khushwant S Bhullar; Naiara Orrego Lagarón; Eileen M McGowan; Indu Parmar; Amitabh Jha; Basil P Hubbard; H P Vasantha Rupasinghe
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.